Reuters logo
BRIEF-Roche Holding says FDA requests phase IB and IB/II Tecentriq study to be placed on partial clinical hold
September 15, 2017 / 3:47 PM / 10 days ago

BRIEF-Roche Holding says FDA requests phase IB and IB/II Tecentriq study to be placed on partial clinical hold

Sept 15 (Reuters) - ROCHE HOLDING AG:

* FDA HAS REQUESTED THAT A PHASE IB AND A PHASE IB/II TECENTRIQ STUDY BE PLACED ON PARTIAL CLINICAL HOLD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below